Marzian Olav
Facharzt für Kinderheilkunde, Hannover.
MMW Fortschr Med. 2007 Jun 28;149(27-28 Suppl):69-74.
For the investigation of the benefits and tolerability of a syrup made of extracts from thyme and ivy (Bronchipret Saft) in children and adolescents (ages: 2-17 years) with acute bronchitis and productive cough, a non-interventional postmarketing surveillance study was carried out.
Prerequisites for participation in the surveillance study were productive cough for a maximum of two days, at least ten coughing fits per day prior to the initiation of treatment (estimation of the parents or adolescent) and a Bronchitis Severity Score (BSS) of at least five points. The primary outcome measure was the change in the clinical symptoms based on the BSS. Treatment was carried out using age-appropriate dosages prescribed by the doctor on a case-by-case basis in accordance with the summary of product characteristics. Documentation of the course of treatment for the surveillance study was to be taken on treatment days 0, 4 and 10.
For the descriptive, statistical evaluation of the surveillance study, the data from 1234 children and adolescents (623 boys and 611 girls) in the age groups < 2 years (N = 12), 2-5 years (N = 372), 6-11 years (N = 438) and 12-17 years (N = 412) were available. The correspondence of the dosages to the age-specific recommendations of the valid summary of product characteristics varied from 81.7% to 93.9% in the different age groups. The average BSS value decreased from 8.8 points to 4.8 on treatment day 4 and to 1.3 points after about ten days of treatment. Compared to that of the initial examination, the number of documented coughing fits had decreased on the average by 18.7 (81.3%) on day 10. The responder rates of the various age groups were 92.0% to 96.5%. The tolerability was rated as very good to good by the physicians in 96.5% of the cases. Two female patients had temporary, not serious adverse drug reactions (stomache ache, mild nausea).
Acute bronchitis with productive cough in (young) children and adolescents can be treated safely and effectively with the thyme and ivy syrup. A ten-day treatment using age-appropriate dosages led to a clear improvement in the symptoms or cure with very good tolerability.
为了研究百里香和常春藤提取物制成的糖浆(Bronchipret糖浆)对患有急性支气管炎且伴有咳痰性咳嗽的儿童和青少年(年龄2至17岁)的疗效和耐受性,开展了一项非干预性上市后监测研究。
参与监测研究的前提条件为咳痰性咳嗽最多持续两天、治疗开始前每天至少有十次咳嗽发作(由父母或青少年估计)以及支气管炎严重程度评分(BSS)至少为五分。主要结局指标是基于BSS的临床症状变化。治疗根据产品特性摘要,由医生根据具体情况按年龄适当剂量进行。监测研究的治疗过程记录应在治疗第0天、第4天和第10天进行。
对于监测研究的描述性统计评估,有1234名儿童和青少年(623名男孩和611名女孩)的数据可供分析,这些儿童和青少年分属不同年龄组:<2岁(N = 12)、2至5岁(N = 372)、6至11岁(N = 438)和12至17岁(N = 412)。不同年龄组中,剂量与有效产品特性摘要中特定年龄建议的符合率在81.7%至93.9%之间。治疗第4天时,BSS平均分值从8.8分降至4.8分,治疗约十天后降至1.3分。与初次检查相比,第10天时记录的咳嗽发作次数平均减少了18.7次(81.3%)。各年龄组的缓解率为92.0%至96.5%。96.5%的病例中,医生对耐受性的评价为非常好至良好。两名女性患者出现了暂时的、不严重的药物不良反应(胃痛、轻度恶心)。
(年幼)儿童和青少年的急性支气管炎伴咳痰性咳嗽可以用百里香和常春藤糖浆安全有效地治疗。采用适合年龄的剂量进行十天治疗可使症状明显改善或治愈,且耐受性良好。